LivaNova Reports Second-Quarter 2023 Results

LONDON–(BUSINESS WIRE)–#advancedcirculatorysupport–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance.


Financial Summary and Highlights1

Second-quarter revenue of $293.9 million increased 15.6% on a reported basis and increased 16.4% on a constant-currency basis, as compared to the prior-year period

Second quarter U.S. GAAP diluted earnings per share was $0.02 and adjusted diluted earnings per share was $0.78

Randomized 150th bipolar depression patient in RECOVER clinical study and initiated interim analyses

Effective May 12, Stephanie Bolton named President of Global Epilepsy following 12 years of LivaNova service, most recently as President of LivaNova’s International Region

“In the second quarter, LivaNova improved profitability and delivered strong revenue growth across all regions,” said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova. “Our performance reflects the effectiveness of our execution in both the Cardiopulmonary and Neuromodulation businesses. I look forward to continuing to work alongside our experienced executive leadership team and colleagues with a focus on patients, performance and execution.”

Second-Quarter 2023 Results

The following table summarizes revenue for the second quarter of 2023 by segment (in millions):

 

Three Months Ended

June 30,

 

% Change

 

Constant-Currency

% Change2

 

2023

 

2022

 

 

Cardiopulmonary

 

$150.6

 

$125.8

 

19.7

%

 

20.9

%

Neuromodulation

 

133.2

 

117.8

 

13.1

%

 

13.5

%

Advanced Circulatory Support

 

9.4

 

9.4

 

0.7

%

 

0.7

%

Other

 

0.7

 

1.2

 

(42.5

)%

 

(43.7

)%

Total Net Revenue

 

$293.9

 

$254.2

 

15.6

%

 

16.4

%

 

• Numbers may not add precisely due to rounding.

Cardiopulmonary revenue increased 20.9%2 versus the second quarter of 2022 with growth across all regions, driven by strong oxygenator demand and increased heart-lung machine placements.

Neuromodulation revenue increased 13.5%2 versus the second quarter of 2022. This increase was driven by growth in new and replacement implants across all regions.

Advanced Circulatory Support (ACS) revenue increased 0.7%2 compared to the second quarter of 2022.

Earnings Analysis

On a U.S. GAAP basis, second quarter 2023 operating income was $17.4 million, as compared to $31.8 million for the second quarter of 2022. Adjusted operating income for the second quarter of 2023 was $49.5 million, as compared to $33.4 million for the second quarter of 2022.

On a U.S. GAAP basis, second-quarter 2023 diluted earnings per share was $0.02, as compared to $0.30 in the second quarter of 2022. Second-quarter 2023 adjusted diluted earnings per share was $0.78, as compared to $0.53 in the second quarter of 2022.

Full-Year 2023 Guidance

LivaNova now expects revenue for full-year 2023 to grow between 8% and 10% on a constant-currency basis. Foreign currency is expected to be a 1% tailwind based on current rates.

Adjusted diluted earnings per share for 2023 are now expected to be in the range of $2.55 to $2.75, assuming a fully diluted share count of 54 million for full-year 2023. The Company now estimates that adjusted free cash flow will be in the range of $85 to $105 million.

As discussed further below, the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Accordingly, the Company is unable to reconcile the forward-looking non-GAAP financial measures included in this section to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts.

Webcast and Conference Call Instructions

The Company will host a live audiocast at 1 p.m. London time (8 a.m. Eastern Time) on Wednesday, July 26, 2023 that will be accessible at www.livanova.com/events. Listeners should register in advance and log on approximately 10 minutes early to ensure proper setup. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 024743. Within 24 hours of the audiocast, a replay will be available at www.livanova.com/events, where it will be archived and accessible for approximately 90 days.

____________________

1

Constant-currency percent change, adjusted operating income, adjusted diluted earnings per share and adjusted free cash flow are non-GAAP measures. For an explanation of these and other non-GAAP measures used in this release, see the section entitled “Use of Non-GAAP Financial Measures.” For reconciliations of certain non-GAAP measures, see the tables that accompany this press release.

2

Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. Constant-currency percent change is a non-GAAP metric. For an explanation of this and other non-GAAP metrics used in this release, see the section entitled “Use of Non-GAAP Financial Measures.”

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Use of Non-GAAP Financial Measures

In this press release, management has disclosed financial measurements that present financial information not in accordance with GAAP. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, operating performance measures as prescribed by GAAP.

Unless otherwise noted, all revenue growth rates in this release reflect comparable, constant-currency percent change. Management believes that referring to comparable, constant-currency percent change is the most useful way to evaluate the revenue performance of LivaNova and to compare the revenue performance of current periods to prior periods on a consistent basis. Constant-currency percent change, a non-GAAP financial measure, measures the change in revenue between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.

LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net revenue growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted diluted earnings per share guidance exclude other items such as, but not limited to, changes in fair value of derivatives and contingent consideration arrangements and asset impairment charges that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for constant-currency net revenue, non-GAAP adjusted tax rate and adjusted diluted earnings per share are net revenue, the effective tax rate and earnings per share, respectively. The most directly comparable GAAP measure for adjusted free cash flow is net cash provided by operating activities. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, the ultimate outcome of legal proceedings, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of derivatives and contingent consideration arrangements, asset impairment charges and the tax impact of the aforementioned items, tax law changes or other tax matters. Accordingly, forward-looking GAAP financial measures and reconciliations to the most directly comparable forward-looking GAAP financial measures are not available without unreasonable effort.

The Company also believes adjusted financial measures such as adjusted gross profit percentage, adjusted selling, general and administrative expense, adjusted research and development expense, adjusted other operating expense, adjusted operating income, adjusted income tax expense, adjusted net income and adjusted diluted earnings per share, are measures by which LivaNova generally uses to facilitate management review of the operational performance of the company, to serve as a basis for strategic planning and to assist in the design of compensation incentive plans. Additionally, the Company also uses the non-GAAP liquidity measure adjusted free cash flow. Furthermore, adjusted financial measures allow investors to evaluate the Company’s core performance for different periods on a more comparable and consistent basis, and with other entities in the medical technology industry by adjusting for items that are not related to the ongoing operations of the Company or incurred in the ordinary course of business.

Safe Harbor Statement

Certain statements in this press release, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. Generally, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this press release, and include, but are not limited to, the following risks and uncertainties: risks related to reductions, interruptions or increasing costs related to the supply of raw materials and components and the distribution of finished products, including as a result of inflation, war and extreme weather; volatility in the global market and worldwide economic conditions, including as caused by the invasion of Ukraine, inflation, foreign exchange fluctuations, changes to existing trade agreements and relationships between the U.S. and other countries including the implementation of sanctions; changes in technology, including the development of superior or alternative technology or devices by competitors and/or competition from providers of alternative medical therapies; failure to obtain approvals or reimbursement in relation to the Company’s products; failure to establish, expand or maintain market acceptance of the Company’s products for the treatment of the Company’s approved indications; failure to develop and commercialize new products and the rate and degree of market acceptance of such products; unfavorable results from clinical studies or failure to meet milestones; failure to comply with, or changes in, laws, regulations or administrative practices affecting government regulation of the Company’s products; risks relating to recalls, enforcement actions or product liability claims; changes or reduction in reimbursement for the Company’s products or failure to comply with rules relating to reimbursement of healthcare goods and services; cyber-attacks or other disruptions to the Company’s information technology systems or those of third parties with which the Company interacts; costs of complying with privacy and security of personal information requirements and laws; failure to comply with anti-bribery laws; risks associated with environmental laws and regulations as well as environmental liabilities, violations, protest voting and litigation; losses or costs from pending or future lawsuits and governmental investigations, including in the case of the Company’s 3T Heater-Cooler and SNIA litigations; product liability, intellectual property, shareholder-related, environmental-related, income tax and other litigation, disputes, losses and costs; failure to retain key personnel, prevent labor shortages, or manage labor costs; the failure of the Company’s R&D efforts to keep up with the rapid pace of technological development in the medical device industry; the impact of climate change and the risk of environmental, social and governance pressures from internal and external stakeholders; the risk of quality concerns and the impacts thereof; failure to protect the Company’s proprietary intellectual property; the potential loss of funds resulting from recent and potential future bank failures; failure of new acquisitions to further the Company’s strategic objectives or strengthen the Company’s existing businesses; the potential for impairments of intangible assets and goodwill; risks relating to the Company’s indebtedness including under the exchangeable senior notes, the Company’s revolving credit facility and the Company’s 2022 Term Facilities, as defined herein; effectiveness of the Company’s internal controls over financial reporting; changes in the Company’s profitability and/or failure to manage costs and expenses; fluctuations in future quarterly operating results and/or variations in revenue and operating expenses relative to estimates; changes in tax laws and regulations, including exposure to additional income tax liabilities; and other unknown or unpredictable factors that could harm the Company’s financial performance.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.

We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

LIVANOVA PLC

NET REVENUE

(U.S. dollars in millions)

 

 

Three Months Ended June 30,

 

 

 

 

 

 

 

 

Constant-Currency

2023

 

2022

 

% Change

% Change (1)

Cardiopulmonary

 

 

 

 

 

 

 

 

US

 

$46.7

 

$37.9

 

23.4

%

 

23.4

%

Europe (2)

 

39.2

 

33.2

 

18.1

%

 

15.7

%

Rest of World

 

64.7

 

54.8

 

18.1

%

 

22.3

%

Total

 

150.6

 

125.8

 

19.7

%

 

20.9

%

Neuromodulation

 

 

 

 

 

 

 

 

US

 

104.1

 

91.4

 

13.8

%

 

13.8

%

Europe (2)

 

15.1

 

13.7

 

10.3

%

 

10.2

%

Rest of World

 

14.0

 

12.7

 

10.6

%

 

14.6

%

Total

 

133.2

 

117.8

 

13.1

%

 

13.5

%

Advanced Circulatory Support

 

 

 

 

 

 

 

 

US

 

9.2

 

8.8

 

4.6

%

 

4.6

%

Europe (2)

 

0.2

 

0.5

 

NM

 

 

NM

 

Rest of World

 

0.1

 

0.1

 

NM

 

 

NM

 

Total

 

9.4

 

9.4

 

0.7

%

 

0.7

%

Other Revenue (3)

 

 

 

 

 

 

 

 

US

 

 

 

N/A

 

 

N/A

 

Europe (2)

 

 

 

N/A

 

 

N/A

 

Rest of World

 

0.7

 

1.2

 

(42.5

)%

 

(43.7

)%

Total

 

0.7

 

1.2

 

(42.5

)%

 

(43.7

)%

Totals

 

 

 

 

 

 

 

 

US

 

160.0

 

138.1

 

15.9

%

 

15.9

%

Europe (2)

 

54.5

 

47.4

 

15.0

%

 

13.2

%

Rest of World

 

79.5

 

68.7

 

15.7

%

 

19.7

%

Total

 

$293.9

 

$254.2

 

15.6

%

 

16.4

%

(1)

Constant-currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.

(2)

Includes countries in Europe where the Company has a direct sales presence. Countries where sales are made through distributors are included in “Rest of World.”

(3)

Other revenue primarily includes rental income not allocated to segments.

NM

Indicates that variance as a percentage is not meaningful.

The revenue results presented are unaudited. Numbers may not add precisely due to rounding.

LIVANOVA PLC

NET REVENUE

(U.S. dollars in millions)

 

 

Six Months Ended June 30,

 

 

2023

 

2022

 

% Change

 

Constant-Currency

% Change (1)

Cardiopulmonary

 

 

 

 

 

 

 

 

US

 

$82.8

 

$76.0

 

9.0

%

 

9.0

%

Europe (2)

 

75.5

 

65.2

 

15.7

%

 

17.4

%

Rest of World

 

124.4

 

101.7

 

22.3

%

 

28.1

%

Total

 

282.7

 

242.9

 

16.4

%

 

19.3

%

Neuromodulation

 

 

 

 

 

 

 

 

US

 

198.6

 

178.6

 

11.1

%

 

11.1

%

Europe (2)

 

28.4

 

26.2

 

8.6

%

 

12.1

%

Rest of World

 

26.9

 

23.2

 

16.1

%

 

21.5

%

Total

 

253.9

 

228.0

 

11.4

%

 

12.3

%

Advanced Circulatory Support

 

 

 

 

 

 

 

 

US

 

18.9

 

19.8

 

(4.5

)%

 

(4.5

)%

Europe (2)

 

0.2

 

1.1

 

NM

 

 

NM

 

Rest of World

 

0.2

 

0.2

 

NM

 

 

NM

 

Total

 

19.3

 

21.0

 

(8.4

)%

 

(8.4

)%

Other Revenue (3)

 

 

 

 

 

 

 

 

US

 

 

 

N/A

 

 

N/A

 

Europe (2)

 

 

 

N/A

 

 

N/A

 

Rest of World

 

1.5

 

2.4

 

(38.4

)%

 

(37.5

)%

Total

 

1.5

 

2.4

 

(38.4

)%

 

(37.5

)%

Totals

 

 

 

 

 

 

 

 

US

 

300.2

 

274.4

 

9.4

%

 

9.4

%

Europe (2)

 

104.1

 

92.5

 

12.5

%

 

14.7

%

Rest of World

 

153.0

 

127.5

 

20.0

%

 

25.6

%

Total

 

$557.3

 

$494.3

 

12.7

%

 

14.6

%

(1)

Constant-currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.

(2)

Includes countries in Europe where the Company has a direct sales presence. Countries where sales are made through distributors are included in “Rest of World.”

(3)

Other revenue primarily includes rental income not allocated to segments.

NM

Indicates that variance as a percentage is not meaningful.

The revenue results presented are unaudited. Numbers may not add precisely due to rounding.

LIVANOVA PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME – UNAUDITED

(U.S. dollars in millions, except per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

 

 

 

2023

 

2022

 

% Change

Net revenue

 

$293.9

 

 

$254.2

 

 

 

Cost of sales

 

88.7

 

 

69.8

 

 

 

Gross profit

 

205.2

 

 

184.4

 

 

11.3

%

Operating expenses:

 

 

 

 

 

 

Selling, general and administrative

 

125.9

 

 

116.5

 

 

 

Research and development

 

51.1

 

 

34.2

 

 

 

Other operating expense

 

10.8

 

 

1.9

 

 

 

Operating income

 

17.4

 

 

31.8

 

 

(45.3

)%

Interest expense

 

(14.8

)

 

(14.4

)

 

 

Foreign exchange and other income/(expense)

 

2.7

 

 

1.6

 

 

 

Income before tax

 

5.3

 

 

19.0

 

 

(72.2

)%

Income tax expense

 

4.1

 

 

2.5

 

 

 

Net income

 

$1.2

 

 

$16.4

 

 

(93.0

)%

 

 

 

 

 

 

 

Basic income per share

 

$0.02

 

 

$0.31

 

 

 

Diluted income per share

 

$0.02

 

 

$0.30

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

Basic

 

53.8

 

 

53.5

 

 

 

Diluted

 

54.0

 

 

54.1

 

 

 

Numbers may not add precisely due to rounding.

Adjusted Financial Measures (U.S. dollars in millions, except per share amounts)

 

 

 

 

 

 

 

 

 

Adjusted (1) Three Months Ended June 30,

 

 

 

 

2023

 

2022

 

% Change

Adjusted SG&A

 

$113.1

 

$101.1

 

11.9

%

Adjusted R&D

 

47.9

 

41.8

 

14.8

%

Adjusted operating income

 

49.5

 

33.4

 

48.4

%

Adjusted net income

 

41.9

 

28.6

 

46.9

%

Adjusted diluted earnings per share

 

$0.78

 

$0.53

 

47.1

%

 

 

 

 

 

 

 

(1)

Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the “Reconciliation of GAAP to non-GAAP Financial Measures” contained in the press release.

Statistics (as a % of net revenue, except for income tax rate)

 

 

 

 

 

 

 

 

 

GAAP Three Months Ended June 30,

 

Adjusted (1) Three Months Ended June 30,

 

 

2023

 

2022

 

2023

 

2022

Gross profit

 

69.8

%

 

72.5

%

 

71.6

%

 

69.3

%

SG&A

 

42.8

%

 

45.8

%

 

38.5

%

 

39.8

%

R&D

 

17.4

%

 

13.5

%

 

16.3

%

 

16.4

%

Operating income

 

5.9

%

 

12.5

%

 

16.8

%

 

13.1

%

Net income

 

0.4

%

 

6.5

%

 

14.3

%

 

11.2

%

Income tax rate

 

77.6

%

 

13.2

%

 

9.5

%

 

4.8

%

(1)

Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the “Reconciliation of GAAP to non-GAAP Financial Measures” contained in the press release.

LIVANOVA PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME – UNAUDITED

(U.S. dollars in millions, except per share amounts)

 

 

 

 

 

 

 

 

 

Six Months Ended June 30,

 

 

 

 

2023

 

2022

 

% Change

Net revenue

 

$557.3

 

 

$494.3

 

 

 

Cost of sales

 

178.0

 

 

141.5

 

 

 

Gross profit

 

379.3

 

 

352.8

 

 

7.5

%

Operating expenses:

 

 

 

 

 

 

Selling, general and administrative

 

250.0

 

 

235.0

 

 

 

Research and development

 

101.1

 

 

75.1

 

 

 

Other operating expenses

 

13.1

 

 

1.4

 

 

 

Operating income

 

15.0

 

 

41.3

 

 

(63.6

)%

Interest expense

 

(28.2

)

 

(22.2

)

 

 

Foreign exchange and other income/(expense)

 

28.3

 

 

5.5

 

 

 

Income before tax

 

15.0

 

 

24.6

 

 

(38.8

)%

Income tax expense

 

6.5

 

 

5.1

 

 

 

Losses from equity method investments

 

(0.1

)

 

(0.1

)

 

 

Net income

 

$8.5

 

 

$19.4

 

 

(56.1

)%

 

 

 

 

 

 

 

Basic income per share

 

$0.16

 

 

$0.36

 

 

 

Diluted income per share

 

$0.16

 

 

$0.36

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

Basic

 

53.7

 

 

53.4

 

 

 

Diluted

 

53.9

 

 

54.1

 

 

 

Numbers may not add precisely due to rounding.

Adjusted Financial Measures (U.S. dollars in millions, except per share amounts)

 

 

 

 

 

Adjusted (1) Six Months Ended June 30,

 

 

2023

2022

% Change

Adjusted SG&A

$221.4

$203.0

9.0

%

Adjusted R&D

94.1

81.8

15.0

%

Adjusted operating income

76.3

61.7

23.6

%

Adjusted net income

65.3

54.6

19.6

%

Adjusted diluted earnings per share

$1.21

$1.01

20.1

%

 

 

 

 

(1)

Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the “Reconciliation of GAAP to non-GAAP Financial Measures” contained in the press release.

Statistics (as a % of net revenue, except for income tax rate)

 

 

 

 

 

 

 

 

 

GAAP Six Months Ended June 30,

 

Adjusted (1) Six Months Ended June 30,

 

 

2023

 

2022

 

2023

 

2022

Gross profit

 

68.1

%

 

71.4

%

 

70.3

%

 

70.1

%

SG&A

 

44.9

%

 

47.5

%

 

39.7

%

 

41.1

%

R&D

 

18.1

%

 

15.2

%

 

16.9

%

 

16.6

%

Operating income

 

2.7

%

 

8.3

%

 

13.7

%

 

12.5

%

Net income

 

1.5

%

 

3.9

%

 

11.7

%

 

11.0

%

Income tax rate

 

43.0

%

 

20.6

%

 

8.4

%

 

6.0

%

 

Contacts

Briana Gotlin

Director, Investor Relations

Phone: +1 281 895 2382

e-mail: [email protected]

Read full story here

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.